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Abstract
Context: Congenital hyperinsulinism (CHI), the commonest cause of persistent hypoglycaemia, has two main histological
subtypes: diffuse and focal. Diffuse CHI, if medically unresponsive, is managed with near-total pancreatectomy. Post-
pancreatectomy, in addition to persistent hypoglycaemia, there is a very high risk of diabetes mellitus and pancreatic
exocrine insufficiency.
Setting: International referral centre for the management of CHI.
Patients: Medically unresponsive diffuse CHI patients managed with near-total pancreatectomy between 1994 and 2012.
Intervention: Near-total pancreatectomy.
Main Outcome Measures: Persistent hypoglycaemia post near-total pancreatectomy, insulin-dependent diabetes mellitus,
clinical and biochemical (faecal elastase 1) pancreatic exocrine insufficiency.
Results: Of more than 300 patients with CHI managed during this time period, 45 children had medically unresponsive
diffuse disease and were managed with near-total pancreatectomy. After near-total pancreatectomy, 60% of children had
persistent hypoglycaemia requiring medical interventions. The incidence of insulin dependent diabetes mellitus was 96% at
11 years after surgery. Thirty-two patients (72%) had biochemical evidence of severe pancreatic exocrine insufficiency
(Faecal elastase 1,100 mg/g). Clinical exocrine insufficiency was observed in 22 (49%) patients. No statistically significant
difference in weight and height standard deviation score (SDS) was found between untreated subclinical pancreatic
exocrine insufficiency patients and treated clinical pancreatic exocrine insufficiency patients.
Conclusions: The outcome of diffuse CHI patients after near-total pancreatectomy is very unsatisfactory. The incidence of
persistent hypoglycaemia and insulin-dependent diabetes mellitus is very high. The presence of clinical rather than
biochemical pancreatic exocrine insufficiency should inform decisions about pancreatic enzyme supplementation.
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Introduction
Congenital hyperinsulinism (CHI) is a major cause of persistent
and recurrent hypoglycaemia in the neonatal and infancy periods
[1]. It is characterized by inappropriate and unregulated secretion
of insulin from pancreatic b-cells in relation to the blood glucose
concentration. CHI is a heterogeneous disease in terms of clinical
presentation, histological subgroups and underlying molecular
genetics. There are 2 main histological subtypes: diffuse (60%–
70% of patients) and focal (30%–40% of patients) [2]. Typically
children with diffuse CHI have homozygous recessive or
compound heterozygous mutations in the ABCC8 or KCNJ11
genes (which encode the SUR1 and Kir6.2 proteins respectively –
the two components of the ATP-sensitive K+ (KATP) channel of the
pancreatic b-cell) [3,4].
Focal CHI is sporadic in inheritance and requires two
independents events: inheritance of a paternal mutation in the
ABCC8 or KCNJ11 gene, and somatic loss of maternal 11p allele
within the focal lesion [5]. Focal CHI is managed with
lesionectomy, whereas first line of treatment for diffuse CHI is
medical management (diazoxide, octreotide and continuous
feeding). If unresponsive to maximum medical management,
children with diffuse CHI are managed with near-total pancre-
atectomy (with high risk of diabetes mellitus).
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A significant percentage of children undergoing near-total
pancreatectomy continue to experience recurrent hypoglycaemia
as well as develop diabetes mellitus eventually [6,7]. Near-total
pancreatectomy is also associated with the risk of pancreatic
exocrine insufficiency. Small studies evaluating long term pancre-
atic exocrine function (using pancreozymin-secretin stimulation
test or 72 hour stool collection) following 85–95% or subtotal
pancreatectomy for CHI have been done [8,9,10,11]. There are a
number of pancreatic function tests available but measurement of
faecal elastase-1 is the currently preferred pancreatic function test
[12].
There are very few studies reporting the long term glucose
metabolism in a large cohort of diffuse CHI patients managed with
near-total pancreatectomy and no large studies assessing pancre-
atic exocrine function after near-total pancreatectomy. We
describe the immediate and long term pancreatic exocrine and
endocrine function in a large cohort of diffuse CHI patients who
underwent near-total pancreatectomy over an 18-years period.
Materials and Methods
The study was approved by the Ethics Committee of Great
Ormond Street Hospital for Children and the Institute of Child
Health, University College London. Informed written consent was
obtained from parents of enrolled children for molecular genetic
testing for CHI (ABCC8/KCNJ11 sequencing).
Among more than 300 patients with CHI managed during this
time period, 45 children had medically unresponsive diffuse
disease and were included in this study. The detailed data about
clinical presentation and management, molecular genetic analysis
results, and post-pancreatectomy periodic assessment of glucose
homeostasis were retrospectively collected by medical case-notes
review.
CHI was diagnosed based on critical blood sample taken during
an episode of spontaneous or provoked hypoglycaemia. Before
2000 when our centre started performing trans-hepatic pancreatic
venous sampling (PVS) for differentiation between diffuse and
focal CHI, all medically unresponsive CHI patients were managed
with near-total pancreatectomy (95% pancreatectomy), the
resection being identical in all patients. Medically unresponsive
diffuse disease was defined as persistent hypoglycaemia with
normal feeding schedule on diazoxide 20 mg/kg/d and/or
octreotide 30 mcg/kg/d and carbohydrate enriched feeds. After
May 2006, we started performing positron emission tomography
using isotope Fluroine-18 L-3, 4-dihydroxyphenyalanine [18F-
DOPA-PET]) to differentiate between diffuse and focal disease.
Biopsies were taken during surgery from various parts of pancreas
and analysed contemporaneously to confirm the diffuse disease
before resection, if not already suspected by genetic analysis. The
diagnosis was subsequently confirmed on histology.
Genetic testing
Genomic DNA was extracted from peripheral leukocytes using
standard procedures. The single-coding exon of the KCNJ11 gene
and the 39 exons of the ABCC8 gene were amplified using the
polymerase chain reaction. Unidirectional sequencing was per-
formed using universal M13 primers and a Big Dye Terminator
Cycler Sequencing Kit v3.1 (Applied Biosystems, Warrington,
UK) according to the manufacturer’s instructions. Reactions were
analysed on an ABI 3730 Capillary sequencer (Applied Biosys-
tems, Warrington, UK) and sequences were compared to the
reference sequences (NM_000525 and NM_000352.2) using
Mutation Surveyor v3.24 (SoftGenetics, PA, USA).
Loss of heterozygosity was investigated by microsatellite analysis
of DNA extracted from paraffin-embedded pancreatic tissue and
peripheral leukocytes. Six markers (D11S2071, D11S1964,
D11S419, D11S1397, D11S1888 and D114138) were amplified
by PCR and allele peak heights were compared using GeneMarker
v1.85 (SoftGenetics, PA, USA).
Pancreatic endocrine assessment
Post-pancreatectomy, periodic 24-hr blood glucose profile,
controlled fast and/or oral glucose tolerance tests were performed
in our centre to assess glucose homeostasis, starting before hospital
discharge after pancreatectomy (immediate outcome). Recurrent
or persistent hypoglycaemia (blood glucose ,3 mmol/l) post-
pancreatectomy was managed with addition of extra carbohydrate
in the feeds, continuous feeds and/or medical therapy with
diazoxide or octreotide. Second pancreatectomy was undertaken if
normoglycaemia could not be achieved with medical manage-
ment. Controlled fast was used to inform decisions about regular
daytime feeds, overnight continuous feeds and extra carbohydrate
in the feeds. Multiple readings of hyperglycaemia (blood glucose.
11 mmol/L) on 24-hour profile was investigated with oral glucose
tolerance test. Diabetes mellitus was diagnosed according to World
Health Organisation criteria. Episodes of postprandial hypergly-
caemia were managed with dietary management. Insulin therapy
was considered when patient developed pre- and postprandial
hyperglycaemia and started in low doses to avoid hypoglycaemia
due to residual endogenous insulin production.
Pancreatic exocrine assessment and Anthropometry
Within 3 months of pancreatectomy, faecal elastase 1 was
measured by sandwich ELISA method utilizing two monoclonal
antibodies highly specific for human pancreatic elastase 1
(ScheBo). A single random stool sample (about 100 mg) was
required. The sample was prepared and analysed according to
manufacturer’s instruction. The detection range was 15 to 500 mg
E1/g stool.
In addition to measurement of faecal elastase 1, patients were
also monitored for clinical symptoms of pancreatic exocrine
insufficiency including pale stools, abdominal discomfort, excessive
flatulence, and poor weight gain. Patients manifesting these
symptoms were managed with pancreatic enzyme replacement
(Creon Micro [Abbott Healthcare, Maidenhead, UK] 100 mg
before each feed or equivalent). Resolution of symptoms on
pancreatic enzyme supplements was used as criteria for clinical
pancreatic exocrine insufficiency.
In patients not requiring pancreatic enzyme supplementation,
faecal elastase 1 was measured annually or at the onset of clinical
pancreatic exocrine insufficiency. In those patients already
commenced on pancreatic enzyme supplementation during
previous assessment, only clinical monitoring was performed.
Correlation between clinical and biochemical pancreatic exocrine
insufficiency was made.
Weight and height from the last clinical assessment was
converted to weight and height standard deviation score (SDS).
Statistical analysis
Data analysis was conducted by using SPSS statistics software,
version 22.0 (IBM SPSS Statistics 22). The normality of the data
was assessed by Shapiro-Wilk test. The medians were compared
using Mann-Whitney U test. A P value,0.05 was considered
statistically significant. The evolution of diabetes mellitus post-
pancreatectomy was estimated using Kaplan-Meier analysis.
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Results
From 1994 to 2012, 45 children underwent near-total
pancreatectomy for management of medically unresponsive diffuse
CHI (table 1). These patients presented with severe hypoketotic,
hypofattyacidaemic hypoglycaemia, biochemical hallmark of
inappropriate insulin secretion. Five patients presented between
1994 and 2000, and underwent near-total pancreatectomy without
undergoing PVS or 18F-DOPA-PET. All five patients had diffuse
disease on histology. Later genetic analysis confirmed four patients
to have biallelic ABCC8 mutation, and one patient to have
paternally inherited monoallelic ABCC8 mutation.
Nine patients with medically unresponsive CHI who presented
between 2000 and May 2006 were diagnosed to have diffuse CHI
on PVS. The remaining medically unresponsive CHI patients who
presented after May 2006 were diagnosed as diffuse CHI either on
the basis of 18F-DOPA-PET or molecular genetic analysis (biallelic
mutations).
Apart from one international patient who developed diabetes
mellitus immediately post-pancreatectomy and was lost to follow-
up, all patients were regularly followed up in our centre at least
until they developed diabetes mellitus.
Pancreatic Endocrine function
Figure 1 shows immediate post-operative pancreatic endocrine
function outcome following near-total pancreatectomy.
Hypoglycaemia
Post-pancreatectomy, 27 children (60%) continued to have
episodes of hypoglycaemia. Hypoglycaemia was less severe as
compared to before pancreatectomy and was successfully managed
with octreotide in 15 (33.3%), diazoxide in 3 (6.6%) and regular
daytime and overnight feeds in 7 (15.6%). Second pancreatectomy
was required in 2 children (4.4%). Over a mean (6 S.D.)/median
(range) follow up period of 6.71 (64.75)/6.52 (0.1–17.5) years,
episodes of hypoglycaemia resolved in 12 children (27%) and the
medical treatments were successfully stopped. Episodes of hypo-
glycaemia persisted up to the age of 7 years in some children. In
the remaining 15 children, the median fasting tolerance was
5 hours (range 3–14 hours) on the current treatment.
Hyperglycaemia
Over a mean (6 S.D.)/median (range) follow up period of 6.71
(64.75)/6.52 (0.1–17.5) years, twenty-two (49%) children devel-
oped hyperglycaemia requiring insulin treatment. Ten children
(22%) developed hyperglycaemia requiring insulin therapy imme-
diately after pancreatectomy. Four of these required insulin
treatment transiently for a period of 6–12 months. The incidence
of hyperglycaemia requiring definitive insulin therapy increased
from 13% immediately post-pancreatectomy to 77% at 7 years
and then to 96% at 11 years post-surgery (figure 2).
Table 1. Characteristics of 45 children managed with near-total pancreatectomy.
Demographics Patients (n) 45
Boys/Girls (n) 20/25
Birth weight (g)* 40896805
Gestational age (weeks)* 3862
Age at presentation (days)# 1 (1–56)
Hypoglycaemia screen Serum glucose (mmol/l)* 1.860.7
Serum Insulin (mU/l)* 34.3642.9
Age at surgery (n) 0–4 weeks 5
5–12 weeks 24
13–52 weeks 12
.52 weeks 4
ABCC8/KCNJ11 mutation analysis (n) Homozygous 10
Compound heterozygous 15
Dominant heterozygous 12
Contiguous gene deletion (Usher’s syndrome) 3
No mutation 5
*Mean6S.D.
#Median (Range).
doi:10.1371/journal.pone.0098054.t001
Figure 1. Immediate outcome of 45 children with medically
unresponsive diffuse CHI managed with near-total pancrea-
tectomy.
doi:10.1371/journal.pone.0098054.g001
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Pancreatic Exocrine function and Anthropometry
Of these 45 children, 32 (72%) had faecal elastase 1 either
undetectable (,15 mg/g of stools) or suggestive of severe
pancreatic exocrine insufficiency (15–100 mg/g of stools). Clinical
pancreatic exocrine insufficiency was diagnosed in 22/45 (49%)
patients. The sensitivity and specificity of faecal elastase 1 for
predicting clinical pancreatic exocrine insufficiency in our series
was 95% and 52% respectively.
In the biochemical pancreatic exocrine insufficiency group
(n = 32), no statistically significant difference was found in age,
weight SDS and height SDS on comparison between subgroups
with treated clinical pancreatic exocrine insufficiency (n = 19) and
untreated subclinical pancreatic exocrine insufficiency (n = 13)
(figure 3).
Discussion
CHI is a heterogeneous disease with regards to responsiveness
to medical treatment. A significant proportion of children require
surgical resection of the pancreas to control the CHI. Most
published series report an unacceptably high incidence of
recurrent hyperinsulinemia following ,95% pancreatectomy,
with need for up to a 98% pancreatectomy in refractory cases
[13,14,15]. In addition to persistent hypoglycaemia, these children
are also at high risk of developing severe pancreatic exocrine
insufficiency and diabetes mellitus.
In our large single centre cohort, 27/45 (60%) children had
persistent hypoglycaemia after near-total pancreatectomy. Meiss-
ner et al published on long-term follow-up of 114 patients with
CHI of all types (focal and diffuse; diazoxide responsive and
unresponsive) [16]. More than half patients in this series (63/114;
55%) required pancreatic surgery comprising of partial (3%),
subtotal (37%) or near-total (15%) pancreatectomy. Persistent
hypoglycaemia was observed in 40% of patients after pancreatic
surgery. However as the data was collected by survey of different
hospitals, there is likely to be an unknown reporting bias in their
study as compared to robust high quality single centre data
presented here.
Similar to our study, Beltrand et al. recently published on
glucose metabolism in 105 children and adolescents with CHI
managed with pancreatectomy, 58 of whom had diffuse CHI and
underwent near-total pancreatectomy. Of these 58 children, 59%
had persistent but mild hypoglycaemia after surgery [6]. As we
report very similar outcome from another large centre, these
findings become of heightened clinical interest and highlight the
consideration for alternative treatment strategies in this disease
such as prolonged intensive medical and nutritional treatment,
with high dose medication.
Leibowitz et al. evaluated endocrine pancreatic function in 14
patients with persistent hyperinsulinaemic hypoglycaemia of
infancy 6.5–21 years after diagnosis, eight of which have been
managed with early subtotal pancreatectomy [17]. In this study,
the insulin response to glucose was blunted in all pancreatecto-
mized patients, and six developed overt diabetes mellitus during
puberty.
Figure 2. Cumulative incidence of definitive insulin therapy in
45 medically unresponsive diffuse CHI patients managed with
near-total pancreatectomy.
doi:10.1371/journal.pone.0098054.g002
Figure 3. Comparison of weight and height SDS between untreated (no pancreatic enzyme supplementation) subclinical group and
treated (appropriate pancreatic enzyme supplementation) clinically symptomatic group using Mann-Whitney U test.
doi:10.1371/journal.pone.0098054.g003
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Cade et al. evaluated six children after pancreatectomy for
persistent hyperinsulinaemic hypoglycaemia of infancy and
reported diabetes mellitus in the only child who had entered
puberty [8]. In our cohort, nearly one-quarter of the patients (10/
45; 22%) developed hyperglycaemia in the days after surgery. Of
these 10 patients with hyperglycaemia after pancreatectomy, 4
(9%) required insulin therapy transiently. The incidence of
definitive insulin therapy increased from 13% postoperatively to
80% at 8 years and then 96% at 11 years post pancreatectomy. As
compared to the study by Beltrand et al., twice number of patients
in our cohort required definitive insulin therapy by 8 years post
pancreatectomy (80% vs 42%). Surprisingly, the incidence of
insulin-dependent diabetes mellitus in a study by Meissner et al.
was only 28% by the mean age of 14 years [16]. This is likely to be
due to more patients undergoing sub-total rather than near-total
pancreatectomy or perhaps healthy remaining pancreatic b-cells
not undergoing apoptosis. The incidence of diabetes mellitus in the
study by Meissner et al. rose to 71% after re-operation for
persistent HH [16].
Fourteen (31%) patients in our study achieved stable euglycae-
mia for more than 2 years duration after pancreatectomy without
the development of hyperglycaemia. Meissner et al. reported
stable long-term euglycaemia after surgery without the need of
further surgery or the development of hyperglycaemia in 27% of
all operated patients [16]. However for this cohort of patients,
surgery was performed without prior investigation for differenti-
ating between focal and diffuse CHI. The authors acknowledged
that focal lesions in the head of the pancreas may have been
missed by blind pancreatic resections. Although equivalent
number of patients achieved stable euglycaemia in our series,
the slightly better outcome as compared to the study by Meissner
et al. could be because of the exclusion of focal lesions in the head
before surgery in our cohort.
Few small studies which have evaluated pancreatic exocrine
function using different methods in this clinical setting have
reported subclinical deficiency rather than clinical exocrine
dysfunction in these patients [8,9,11]. Dunger et al. reported low
trypsin, amylase and bicarbonate concentrations with cholecysto-
kinin-secretin test in approximately two-thirds of their patients
who had 95% pancreatectomy whereas Rother et al. reported
normal pancreatic exocrine function based on clinical history and
72-h stool collection in eight children after subtotal pancreatec-
tomy for CHI [9,11]. Though cholecystokinin-secretion test or one
of its modifications are the gold standard for pancreatic exocrine
function, they have drawbacks of being time consuming, invasive
and not being routinely available in clinical practice. In addition,
there are no standardized enzyme cut-off values or agreement
between centres as to which parameter is the most specific for the
assessment of pancreatic function.
Measurement of faecal elastase 1 is the currently preferred
pancreatic function test and is the new gold standard for non-
invasive pancreatic function testing. Faecal elastase 1 is a
pancreas-specific proteolytic enzyme that binds to bile salts and
is not degraded during its passage through the gut, unlike other
pancreatic enzymes [18]. Studies have shown that measurement of
faecal elastase 1 correlates well with pancreatic output of elastase-1
and other pancreatic enzymes such as amylase, lipase and trypsin
[19]. A faecal elastase 1 value of ,200 mg/g of stool is the cut-off
for pancreatic exocrine insufficiency. To the best of our
knowledge, there are no studies assessing pancreatic exocrine
function following pancreatectomy utilizing measurement of faecal
elastase 1. It is unclear whether subclinical pancreatic exocrine
deficient patients will benefit from pancreatic enzyme supplemen-
tation.
In our cohort, nearly three-quarter patients (32/45; 72%) had
either undetectable faecal elastase 1 or in the severe pancreatic
exocrine insufficiency range. Clinical pancreatic exocrine insuffi-
ciency was evident in 22/45 (49%) patients requiring pancreatic
enzyme supplementation. In nearly one-quarter of the patients
(12/45; 27%), no correlation between the biochemical and clinical
pancreatic exocrine insufficiency was observed. No statistically
significant difference was observed in weight and height SDS
between treated subclinical pancreatic exocrine deficient patients
and treated clinical pancreatic exocrine insufficiency patients
(figures 3).
We acknowledge that faecal elastase 1 is an indirect pancreatic
function test and is likely to be more prone to errors than the direct
pancreatic function tests but because of its simple technique is used
most often in the setting likely to result in pancreatic exocrine
insufficiency such as post-pancreatectomy. With the increased
awareness of CHI, need for appropriate management to avoid
poor neurological outcome (near-total pancreatectomy in medi-
cally unresponsive diffuse disease), and advancement in the
radiological (18F DOPA-PET CT) and laparoscopic surgical
techniques, clinicians are likely to come across post-pancreatecto-
my biochemical pancreatic exocrine insufficiency scenario. Our
results highlight that faecal elastase-1 has poor specificity and
should be cautiously interpreted in absence of clinical pancreatic
exocrine insufficiency to inform clinical decisions about pancreatic
enzyme replacement treatment.
In our cohort, although a number of patients had monoallelic
ABCC8/KCNJ11 mutations which usually results either in mild
diazoxide responsive CHI or focal CHI if paternally inherited and
associated with somatic loss of maternal 11p allele, detailed
evaluation did not show response to medical therapy and histology
showed diffuse disease. Diazoxide unresponsive diffuse CHI has
been reported in association with dominant heterozygous ABCC8/
KCNJ11 mutations [20]. Another plausible hypothesis is that some
of these patients may have a deep intronic mutation on the second
allele that was not identified on Sanger sequencing or have a
different mechanism of diffuse CHI [21].
A limitation of this study is its retrospective nature. In addition,
the data presented here span a period of nearly two decades
during which there were a number of significant advances in the
management of CHI (introduction of PVS and 18F DOPA-PET
CT) and hence changes in the algorithms for the management.
Despite these limitations, our robust single centre data on a large
cohort of a complex group of CHI patients highlights the need for
research for alternative treatment strategies in this disease.
Conclusions
In conclusion, long-term follow up a large cohort of medically
unresponsive diffuse CHI patients has shown that milder
hypoglycaemia persisted in 60% patients in this CHI subgroup
after near-total pancreatectomy. The incidence of insulin depen-
dent diabetes mellitus was nearly 100% after 11 years post-
pancreatectomy. There seems to be poor correlation between the
biochemical (faecal elastase 1) and clinical evidence of pancreatic
exocrine insufficiency. Untreated subclinically pancreatic exocrine
deficient children thrive as well as treated clinically pancreatic
exocrine deficient children.
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